Scarica l'app Stockscreener
2.85
0.35%
0.01
Dopo l'orario di chiusura:
2.95
0.10
+3.51%
Precedente Chiudi:
$2.84
Aprire:
$2.81
Volume 24 ore:
2.81M
Relative Volume:
1.80
Capitalizzazione di mercato:
$192.62M
Reddito:
$6.96M
Utile/perdita netta:
$-46.51M
Rapporto P/E:
-34.93
EPS:
-0.0816
Flusso di cassa netto:
$-37.99M
1 W Prestazione:
-18.10%
1M Prestazione:
-53.81%
6M Prestazione:
-73.24%
1 anno Prestazione:
-16.67%
Intervallo 1D:
$2.80
$2.96
Intervallo di 1 settimana:
$2.70
$3.60
Portata 52W:
$2.70
$19.05
Perspective Therapeutics Inc Stock (CATX) Company Profile
Nome
Perspective Therapeutics Inc
Settore
Industria
Telefono
509-375-1202
Indirizzo
350 Hills Street, Suite 106, Richland
Confronta CATX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
2.85 | 192.62M | 6.96M | -46.51M | -37.99M | -0.1716 |
|
ABT
Abbott Laboratories
|
114.23 | 198.13B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
364.60 | 138.99B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
88.95 | 131.10B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
81.03 | 103.90B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
74.81 | 44.12B | 6.60B | 4.16B | 490.10M | 6.93 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-25 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-01 | Iniziato | Wedbush | Outperform |
| 2024-09-25 | Iniziato | Truist | Buy |
| 2024-07-25 | Iniziato | BofA Securities | Buy |
| 2024-05-09 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Perspective Therapeutics Inc Borsa (CATX) Ultime notizie
Minerva Surgical (NASDAQ:UTRS) versus Perspective Therapeutics (NYSE:CATX) Financial Contrast - Defense World
Perspective Therapeutics: Definitely Not Looking Overvalued Now - Seeking Alpha
Pliant Therapeutics Inc (PLRX): A New Perspective - Stocks Register
Neuroendocrine Tumor Market to Reach New Heights in Growth by 2034, DelveInsight Predicts - News Channel Nebraska
Targeted Alpha Therapy Market, Drugs Approval, Proprietary Technologies & Clinical Trials: 20+ Drugs of Targeted Alpha Therapy In Clinical Trials - GlobeNewswire Inc.
Perspective Therapeutics' SWOT analysis: radiopharmaceutical stock faces pivotal moment - Investing.com
BNP Paribas Financial Markets Buys 44,174 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Charles Schwab Investment Management Inc. Acquires 298,778 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Acquired by Charles Schwab Investment Management Inc. - MarketBeat
Walleye Capital LLC Sells 494,706 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - MarketBeat
Perspective Therapeutics, Inc. (NYSE:CATX) Director Acquires $100,003.75 in Stock - MarketBeat
Janus Henderson Group PLC Has $64.01 Million Stake in Perspective Therapeutics, Inc. (NYSE:CATX) - MarketBeat
Fmr LLC Purchases 5,370,392 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - MarketBeat
Perspective Therapeutics CEO Johan Spoor buys $30,132 in stock By Investing.com - Investing.com Canada
Perspective Therapeutics CEO Johan Spoor buys $30,132 in stock - Investing.com India
Perspective Therapeutics, Inc. (NYSE:CATX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Perspective Therapeutics CFO Jonathan Hunt acquires $48,974 in stock - Investing.com India
Perspective Therapeutics CFO Jonathan Hunt acquires $48,974 in stock By Investing.com - Investing.com Nigeria
Perspective Therapeutics selloff a buying opportunity, says JonesResearch - MSN
Insider Buying: Jonathan Hunt Acquires Shares of Perspective The - GuruFocus.com
Perspective Therapeutics director Robert Williamson acquires shares worth $22,813 - Investing.com
Jonathan Robert Hunt Acquires 12,829 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) Stock - MarketBeat
Perspective Therapeutics to Participate in Upcoming Investor Conferences in December - The Manila Times
Perspective Therapeutics to Present at Piper and Evercore Healthcare Conferences in December | CATX Stock News - StockTitan
Perspective Therapeutics (NYSE:CATX) Rating Lowered to “Neutral” at Bank of America - Defense World
Perspective Therapeutics price target lowered to $9 from $17 at B. Riley - TipRanks
Perspective Therapeutics, Inc. (NYSE:CATX) CEO Johan M. Spoor Acquires 14,500 Shares - MarketBeat
Perspective Therapeutics CEO Johan Spoor buys $100,468 in stock - Investing.com
Perspective Therapeutics price target lowered to $16 from $25 at RBC Capital - Yahoo Finance
Perspective Therapeutics downgraded to Neutral from Buy at BofA - Yahoo Finance
Perspective Therapeutics (NYSE:CATX) Price Target Cut to $16.00 by Analysts at Oppenheimer - Defense World
Perspective Therapeutics' SWOT analysis: radiopharmaceutical stock faces challenges, opportunities - Investing.com
Perspective Therapeutics shares hold Outperform as RBC adjusts expectations for progress - Investing.com Nigeria
Perspective Therapeutics (NYSE:CATX) Rating Lowered to Neutral at Bank of America - MarketBeat
Autonomix Medical (NASDAQ:AMIX) vs. Perspective Therapeutics (NYSE:CATX) Critical Review - Defense World
Perspective Therapeutics stock downgraded to Neutral By Investing.com - Investing.com Nigeria
Perspective Therapeutics stock downgraded to Neutral - Investing.com India
Perspective Therapeutics price target lowered to $16 from $22 at Oppenheimer - TipRanks
Stock market news: Perspective Therapeutics -44.33%, Pyxis Oncology -42.93% among top losers during mid day trading - Business Upturn
Stock market news: SKK Holdings Limited declined by 51.53% while SCWorx Corp. surged by 101.02% during mid day trading - Business Upturn
Dow Jumps Over 100 Points; Nvidia Posts Upbeat Earnings - Benzinga
Stock market today: Pyxis Oncology plunges by 47.25% while Perspective Therapeutics declines by 46.68% in early trading - Business Upturn
Stock market today: SCWorx Corp. gains 141.81% while Pyxis Oncology down by 46.41% in early trading - Business Upturn
Perspective stock slips after radio pharma data (CATX:NYSE) - Seeking Alpha
Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium - The Manila Times
Cantor Fitzgerald Has Positive View of CATX FY2024 Earnings - MarketBeat
Perspective Therapeutics Inc Azioni (CATX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.54%
Capitalizzazione:
|
Volume (24 ore):